Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.

Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ.

Cancer Immunol Res. 2018 Sep 12. doi: 10.1158/2326-6066.CIR-18-0309. [Epub ahead of print]

PMID:
30209061
2.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

3.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

4.

Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K.

Mol Ther. 2012 Oct;20(10):1998-2003. doi: 10.1038/mt.2012.146. Epub 2012 Aug 7.

5.

Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, Vile RG.

Cancer Res. 2012 Sep 15;72(18):4753-64. doi: 10.1158/0008-5472.CAN-12-0600. Epub 2012 Jul 26.

6.

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Kaluza KM, Thompson JM, Kottke TJ, Flynn Gilmer HC, Knutson DL, Vile RG.

Int J Cancer. 2012 Aug 15;131(4):844-54. doi: 10.1002/ijc.26447. Epub 2011 Nov 30.

7.

Apoptosis-associated caspase activation assays.

Kaufmann SH, Lee SH, Meng XW, Loegering DA, Kottke TJ, Henzing AJ, Ruchaud S, Samejima K, Earnshaw WC.

Methods. 2008 Mar;44(3):262-72. doi: 10.1016/j.ymeth.2007.11.005. Review.

PMID:
18314058
8.

Analysis of caspase activation during apoptosis.

Kaufmann SH, Kottke TJ, Martins LM, Henzing AJ, Earnshaw WC.

Curr Protoc Cell Biol. 2001 Aug;Chapter 18:Unit 18.2. doi: 10.1002/0471143030.cb1802s11.

PMID:
18228341
9.

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C.

Clin Cancer Res. 2005 Sep 15;11(18):6641-9.

10.

Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro.

Meng XW, Chandra J, Loegering D, Van Becelaere K, Kottke TJ, Gore SD, Karp JE, Sebolt-Leopold J, Kaufmann SH.

J Biol Chem. 2003 Nov 21;278(47):47326-39. Epub 2003 Sep 8.

11.

G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells.

Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH.

J Clin Invest. 2002 Jul;110(1):91-9.

12.

Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation.

Ruchaud S, Korfali N, Villa P, Kottke TJ, Dingwall C, Kaufmann SH, Earnshaw WC.

EMBO J. 2002 Apr 15;21(8):1967-77.

13.

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH.

Blood. 2002 Jan 15;99(2):664-71.

14.

Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells.

Kottke TJ, Blajeski AL, Meng XW, Svingen PA, Ruchaud S, Mesner PW Jr, Boerner SA, Samejima K, Henriquez NV, Chilcote TJ, Lord J, Salmon M, Earnshaw WC, Kaufmann SH.

J Biol Chem. 2002 Jan 4;277(1):804-15. Epub 2001 Oct 24.

15.

A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines.

Blajeski AL, Kottke TJ, Kaufmann SH.

Exp Cell Res. 2001 Nov 1;270(2):277-88.

PMID:
11640891
17.

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J.

Blood. 2001 Jun 1;97(11):3361-9.

18.

Flavopiridol binds to duplex DNA.

Bible KC, Bible RH Jr, Kottke TJ, Svingen PA, Xu K, Pang YP, Hajdu E, Kaufmann SH.

Cancer Res. 2000 May 1;60(9):2419-28.

19.

Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.

Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt D Jr, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB, Kaufmann SH.

Clin Cancer Res. 2000 Feb;6(2):661-70.

20.

Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.

Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA, Kaufmann SH.

Clin Cancer Res. 2000 Jan;6(1):237-49.

21.

Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile.

Mesner PW Jr, Bible KC, Martins LM, Kottke TJ, Srinivasula SM, Svingen PA, Chilcote TJ, Basi GS, Tung JS, Krajewski S, Reed JC, Alnemri ES, Earnshaw WC, Kaufmann SH.

J Biol Chem. 1999 Aug 6;274(32):22635-45.

22.

Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis.

Kottke TJ, Blajeski AL, Martins LM, Mesner PW Jr, Davidson NE, Earnshaw WC, Armstrong DK, Kaufmann SH.

J Biol Chem. 1999 May 28;274(22):15927-36.

23.
24.

Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution.

Samejima K, Toné S, Kottke TJ, Enari M, Sakahira H, Cooke CA, Durrieu F, Martins LM, Nagata S, Kaufmann SH, Earnshaw WC.

J Cell Biol. 1998 Oct 5;143(1):225-39.

25.

Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells.

Karnes WE Jr, Weller SG, Adjei PN, Kottke TJ, Glenn KS, Gores GJ, Kaufmann SH.

Gastroenterology. 1998 May;114(5):930-9.

PMID:
9558281
26.

Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis.

Martins LM, Mesner PW, Kottke TJ, Basi GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, Earnshaw WC, Kaufmann SH.

Blood. 1997 Dec 1;90(11):4283-96.

27.

Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.

Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH.

Blood. 1997 Aug 1;90(3):935-43.

28.

Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.

Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH.

Clin Cancer Res. 1997 May;3(5):761-70.

Supplemental Content

Loading ...
Support Center